• LAST PRICE
    45.5600
  • TODAY'S CHANGE (%)
    Trending Up0.9200 (2.0609%)
  • Bid / Lots
    41.8400/ 1
  • Ask / Lots
    53.0000/ 1
  • Open / Previous Close
    44.6100 / 44.6400
  • Day Range
    Low 44.6100
    High 46.3300
  • 52 Week Range
    Low 3.6900
    High 53.8200
  • Volume
    175,399
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 44.64
TimeVolumeSLNO
09:32 ET129944.725
09:34 ET10044.885
09:39 ET20044.84
09:41 ET50045
09:43 ET10045.155
09:52 ET10044.94
09:59 ET10044.918
10:03 ET110045.04
10:06 ET50045
10:08 ET10045.215
10:12 ET10044.955
10:14 ET390045.1935
10:17 ET30045.18
10:21 ET10045.45
10:24 ET10045.48
10:28 ET120045.3622
10:32 ET20445.45
10:33 ET60045.5201
10:35 ET30045.715
10:39 ET1303246.33
10:42 ET232446
10:44 ET10046
10:46 ET62645.64
10:48 ET10545.615
10:50 ET10045.495
10:51 ET20045.435
10:53 ET191545.59
10:57 ET10045.485
11:00 ET150845.69
11:02 ET20045.74
11:04 ET10045.735
11:08 ET60045.66
11:18 ET20045.68
11:20 ET20045.76
11:22 ET50045.655
11:24 ET73545.77
11:26 ET10045.84
11:29 ET90045.73
11:36 ET11145.75
11:38 ET10045.74
11:45 ET10045.66
11:51 ET20045.82
12:00 ET11645.82
12:02 ET70045.68
12:07 ET80045.665
12:09 ET60045.65
12:12 ET121345.625
12:14 ET20045.645
12:16 ET20045.64
12:18 ET150045.95
12:21 ET10045.88
12:23 ET30045.94
12:25 ET20045.97
12:27 ET322945.93
12:32 ET110045.915
12:34 ET20045.84
12:38 ET10045.89
12:39 ET30045.9
12:43 ET10045.85
12:45 ET10045.88
12:48 ET80045.77
12:52 ET10045.755
12:56 ET20045.65
01:03 ET10045.675
01:06 ET10045.61
01:10 ET63245.715
01:12 ET60045.53
01:14 ET20045.57
01:17 ET149845.565
01:19 ET10045.565
01:24 ET50045.69
01:26 ET20045.82
01:32 ET120045.6
01:33 ET10045.605
01:37 ET10045.61
01:44 ET10045.59
01:48 ET10045.595
01:50 ET20045.595
01:51 ET160045.6
01:57 ET105546.07
02:00 ET10046.13
02:02 ET51145.985
02:06 ET10045.93
02:09 ET30245.84
02:20 ET20045.9
02:22 ET10046
02:24 ET150045.99
02:26 ET20045.88
02:27 ET10045.88
02:31 ET10045.865
02:33 ET20045.88
02:36 ET20045.95
02:38 ET10045.84
02:40 ET60045.79
02:44 ET40045.5725
02:45 ET40045.525
02:47 ET22445.485
02:49 ET20045.45
02:51 ET70045.475
02:54 ET170145.68
02:56 ET30045.765
02:58 ET10045.84
03:02 ET10045.815
03:03 ET30845.865
03:07 ET10045.81
03:09 ET10045.82
03:12 ET10045.77
03:14 ET70045.8
03:16 ET20045.895
03:18 ET10045.85
03:20 ET60045.78
03:23 ET10045.845
03:25 ET30045.86
03:27 ET10045.915
03:30 ET140845.85
03:32 ET49645.81
03:34 ET30045.838
03:36 ET130045.865
03:38 ET130045.885
03:39 ET40045.92
03:41 ET10045.885
03:43 ET50045.85
03:45 ET151245.69
03:48 ET10045.725
03:50 ET101945.84
03:52 ET142945.835
03:54 ET227545.65
03:56 ET160045.6
03:57 ET97945.6
03:59 ET2703245.56
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSLNO
Soleno Therapeutics Inc
1.4B
-17.0x
---
United StatesBLTE
Belite Bio Inc
1.5B
-41.2x
---
United StatesAKRO
Akero Therapeutics Inc
1.3B
-7.2x
---
United StatesMORF
Morphic Holding Inc
1.5B
-8.8x
---
United StatesCGEM
Cullinan Therapeutics Inc
1.3B
-7.1x
---
United StatesKURA
Kura Oncology Inc
1.6B
-10.0x
---
As of 2024-06-09

Company Information

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.

Contact Information

Headquarters
203 Redwood Shores Parkway, Suite 500REDWOOD CITY, CA, United States 94065
Phone
650-213-8444
Fax
302-655-5049

Executives

Independent Chairman of the Board
Ernest Mario
President, Chief Executive Officer, Chief Operating Officer, Director
Anish Bhatnagar
Chief Financial Officer
James Mackaness
Senior Vice President - Clinical Development
Michael Huang
Senior Vice President - Clinical Operations
Kristen Yen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.5B
Revenue (TTM)
$0.00
Shares Outstanding
34.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-1.38
EPS
$-2.68
Book Value
$4.97
P/E Ratio
-17.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.